Skip to main content
Premium Trial:

Request an Annual Quote

Opko to Sell $100M Shares in Public Offering

Premium

Opko Health said this week that it intends to sell $100 million of its common stock in an underwritten public offering.

Proceeds of the offering will be used for general corporate purposes, which may include research and development expenses, clinical trials, the acquisition of new technologies and businesses and other business opportunities, the company said.

Opko entered the RNAi therapeutics space with its 2007 merger with Acuity Pharmaceuticals (GSN 3/29/2007). Earlier this year, the company bought non-coding RNA drug developer Curna for $10 million (GSN 2/3/2011).

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.